Core Points - Rosen Law Firm is encouraging investors of Marex Group plc who incurred losses exceeding $100,000 during the Class Period from May 16, 2024, to August 5, 2025, to secure legal counsel before the December 8, 2025, deadline for lead plaintiff applications [1][5]. Group 1: Legal Action Details - Investors who purchased Marex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in securing significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4].

Core Points - Rosen Law Firm is reminding investors who purchased Marex Group plc securities between May 16, 2024, and August 5, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Marex securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by December 8, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - It is claimed that Marex's financial statements could not be relied upon, and positive statements about the company's business were materially misleading [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit set for December 8, 2025 [3][8]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements, failing to disclose significant issues such as selling over-the-counter financial instruments to itself and inconsistencies in financial statements [6]. - A report by NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [7]. - Following the release of the report, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 [9]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [2]. - The role of lead plaintiff in the class action lawsuit is designated for the investor with the largest financial interest, who will oversee the litigation on behalf of the class [10]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Marex's conduct [11].

Core Viewpoint - Rosen Law Firm is encouraging investors of Marex Group plc who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 8, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - The class period for the Marex Group plc securities class action is from May 16, 2024, to August 5, 2025 [1]. - Investors who purchased Marex securities during this period may be eligible for compensation without any upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors must apply by December 8, 2025, to serve as lead plaintiff, representing other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements secured for investors [4]. Group 3: Allegations Against Marex - The lawsuit alleges that during the class period, Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - As a result of these actions, Marex's financial statements were deemed unreliable, leading to misleading positive statements about the company's business and operations [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status by December 8, 2025 [1][3]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false or misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [3]. - Specific allegations include a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, with examples such as a $17 million fabricated receivable and nearly $1 billion in concealed derivatives exposure [4]. - Following the release of a damaging report, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 on heavy trading volume [5]. Group 2: Legal Proceedings and Investor Actions - The lead plaintiff in the class action will be the investor with the largest financial interest who is adequate and typical of class members, and any member of the class may move to serve as lead plaintiff [6]. - Faruqi & Faruqi encourages individuals with information regarding Marex's conduct, including whistleblowers and former employees, to come forward [6].

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Marex Group plc ("Marex Group plc" or the "Company") (NASDAQ: MRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Marex Group plc investors who were adversely affected by alleged securities fraud between May 16, 2024 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/marex-group-plc-l ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Marex Group plc (NASDAQ: MRX). Shareholders who purchased shares of MRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/marex-group-plc-loss-submission-form/?id=178113&f ...

Core Viewpoint - Rosen Law Firm is encouraging investors of Marex Group plc to secure legal counsel before the December 8, 2025 deadline for a securities class action lawsuit related to misleading financial statements and practices [2][6]. Group 1: Class Action Details - The class action pertains to investors who purchased Marex securities between May 16, 2024, and August 5, 2025, and may be entitled to compensation without upfront fees through a contingency fee arrangement [2][3]. - The lawsuit alleges that Marex made materially false statements and failed to disclose critical information regarding its financial practices, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a significant settlement against a Chinese company and has recovered hundreds of millions for investors [5].

Core Points - Rosen Law Firm is reminding investors who purchased Marex Group plc securities between May 16, 2024, and August 5, 2025, of the December 8, 2025, lead plaintiff deadline [1] - Investors may be entitled to compensation through a contingency fee arrangement without any out-of-pocket costs [1] Case Details - The lawsuit alleges that during the Class Period, Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements between subsidiaries [4] - As a result of these issues, Marex's financial statements were deemed unreliable, and positive statements about the company's business were misleading [4] Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [3]

Core Insights - Marex Group plc has launched its structured products business in the United States to meet the demand from registered investment advisors, broker-dealers, and private banks for issuer and credit diversification [1][2][4] - The US structured products market is projected to reach $220 billion in 2025, indicating a significant growth opportunity for Marex as a new non-bank issuer [4] - Marex aims to provide a broad range of structured investment solutions, leveraging its global expertise to enhance product offerings for financial professionals [3][5] Company Overview - Marex Group plc is a diversified global financial services platform that offers essential liquidity, market access, and infrastructure services across energy, commodities, and financial markets [6][7] - The company has issued over 20,000 structured products globally, positioning itself as a significant player in the structured products market [2] - Marex operates with a different credit risk profile compared to traditional bank issuers, providing a unique value proposition for credit risk diversification [4][5] Leadership and Strategy - Scott Kerbel has been appointed as the Head of US Distribution for Marex Financial Products, bringing over 20 years of structured investment experience from major financial institutions [4][5] - The company is expanding its US team to enhance client coverage and strengthen relationships with financial professionals, reflecting its commitment to growth in the Americas [4][5] - Marex's structured products initiative is designed to offer greater choice and clarity for advisors, aligning with their clients' investment objectives [5]